Comparison of [111In]pentetreotide-SPECT and [18F]FDOPA-PET in the localization of extra-adrenal paragangliomas: the case for a patient-tailored use of nuclear imaging modalities

Autor:	Anne Barlier, Stéphane Garcia, C. De Micco, I. Morange, F. Sebag, Julien Mancini, F. F. Palazzo, M. Zanaret, Jean-Pierre Lavieille, Jf Henry, N. Charrier, Olivier Mundler, Nicolas Fakhry, David Taïeb, B. Gaborit, Arnaud Deveze, E. Carmona
Rok vydání:	2010
Předmět:	Nuclear imaging business.industry Endocrinology Diabetes and Metabolism Lesion chemistry.chemical_compound Endocrinology 18f fdopa Germline mutation chemistry parasitic diseases 111In-Pentetreotide Medicine SDHD medicine.symptom business Nuclear medicine Prospective cohort study Metanephrine
Zdroj:	Clinical Endocrinology. 74:21-29
ISSN:	0300-0664
DOI:	10.1111/j.1365-2265.2010.03893.x
Popis:	Summary Aims and methods The aim of this prospective study was to compare the diagnostic value of [18F]FDOPA-PET and [111In]pentetreotide-SPECT somatostatin receptor scintigraphy (SRS) in patients with nonmetastatic extra-adrenal paragangliomas (PGLs). Twenty-five consecutive unrelated patients who were known or suspected of having nonmetastatic extra-adrenal PGLs were prospectively evaluated with SRS and [18F]FDOPA-PET. 131I-MIBG and [18F]FDG-PET were added to the work-up in patients with a personal or familial history of PGL, predisposing mutations, abdominal PGLs, metanephrine hypersecretion and abdominal foci on SRS and/or [18F]FDOPA-PET. Results SRS correctly detected 23/45 lesions of which 20 were head or neck lesions (H&N) and 3 were abdominal lesions. [18F]FDOPA-PET detected significantly more lesions than SRS (39/45, P
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::32b2893e205764726e3e2a04507722cd https://doi.org/10.1111/j.1365-2265.2010.03893.x Zobrazit plný text záznamu Plný text